Expression of chemokine receptors on Th1/Th2 CD4+ lymphocytes in patients with multiple sclerosis.
Expression of chemokine receptors on Th1/Th2 CD4+ lymphocytes in patients with multiple sclerosis.
复制标题
DOI：
--
复制
发表时间：
2011-03
期刊：
影响因子：
--
通讯作者：
A. Andalib;Hassan Doulabi;M. Najafi;M. Tazhibi;A. Rezaie
中科院分区：
文献类型：
--
作者：
A. Andalib;Hassan Doulabi;M. Najafi;M. Tazhibi;A. Rezaie
Th 1细胞优先表达CXCR 3、CCR 5和CCR 6，而CCR 3和CCR 4主要由Th 2细胞亚群表达。多发性硬化（MS）是一种Th 1细胞依赖性的中枢神经系统慢性炎症性疾病，免疫调节性细胞因子可改变这些淋巴细胞亚群的趋化因子表达模式。目的通过检测CD 4 T细胞表面趋化因子受体的表达，评价IFN-β治疗后患者的Th 1/Th 2优势。方法采用流式细胞术检测MS患者和健康对照者外周血单个核细胞（PBMCs）中CD 4 T细胞群趋化因子受体的表达。26例MS患者在IFN-β治疗前后参加了这项研究，并纳入了相同数量的健康个体。结果MS组外周血淋巴细胞百分率为41.28% ± 10.30%，对照组为36.88% ± 5.51%，两组比较差异有统计学意义（P=0.017）。CD 4 + CXCR 3+细胞在健康组为18.86% ± 8.46%，MS治疗前为30.78% ± 9.8%，治疗后为21.06% ± 9.23%（P<0.001）。CD 4 + CCR 4+细胞亚群在健康组为27.35% ± 10.15%，IFN-β治疗前为28.17% ± 8.9%，IFN-β治疗后为34.20% ± 8.96%。IFN-β治疗后CD 4 + CCR 4+亚群占优势，与对照组比较差异有显著性（P<0.001）。CD 4 + CCR 5+百分比在健康人中为1.24% ± 0.92%，在MS患者中为1.23% ± 0.71%，在治疗后状态中为0.76% ± 0.49%（p=0.003）。CD 4 + CCR 3+细胞亚群在对照组中为0.62% ± 0.67%，在MS患者中为0.28% ± 0.26%（p=0.022），在IFN-β治疗的患者中为0.39% ± 0.54%（p=0.334）。CXCR 3表达在治疗前和治疗后状态（r=0.840，p<0.001）以及CCR 4+表达（r=0.712，p<0.001）在相同组中被发现相关。IFN-β治疗前以Th 1为主，治疗后转为Th 2为主。结论Th 1/Th 2细胞亚群趋化因子受体的表达可用于MS病情的监测和评估。
BACKGROUND Th1 cells preferentially express CXCR3, CCR5 and CCR6, while CCR3 and CCR4 are predominantly expressed by Th2 cell subsets. Multiple Sclerosis (MS) is a Th1 cell-dependant chronic inflammatory disease of the central nervous system, and immunomudolatory cytokines could alter the chemokine expression pattern of these lymphocyte subsets. OBJECTIVE This study was performed to measure chemokine receptor expression on CD4 T cells for evaluation of Th1/Th2 dominantly in IFN-β treated patients. METHODS Flowcytometry was used to detect chemokine receptor expression on CD4 T cell population in PBMCs obtained from MS and healthy control groups. Twenty six MS patients participated in this study before and after IFN-β therapy and the same number of healthy individuals were included. RESULTS The percentage of lymphocytes was 41.28% ± 10.30% 2 in the blood of MS group compared with 36.88% ± 5.51% in the control group (p=0.017). The CD4+CXCR3+ cells were 18.86% ± 8.46% in healthy group, 30.78% ± 9.8% in pre-treated MS patients and 21.06% ± 9.23% in post-treated group (p<0.001). The CD4+CCR4+ cell subsets were 27.35% ± 10.15% in healthy group; 28.17% ± 8.9% in pre-treated group and 34.20% ± 8.96% in the post-IFN-β treatment group. The subset of CD4+CCR4+ was found to be dominant after IFN-β therapy in comparison with the control group (p<0.001). CD4+CCR5+ percentage was 1.24% ± 0.92% in the healthy people, 1.23% ± 0.71% in the MS patients and 0.76% ± 0.49% in post-treatment status (p=0.003). CD4+CCR3+ cell subsets were 0.62% ± 0.67% in control group, 0.28% ± 0.26% in the MS patients (p=0.022) and 0.39% ± 0.54% in IFN-β treated patients (p=0.334). An association was found for CXCR3 expression in pre- and post-treatment status (r=0.840, p<0.001) as well as for CCR4+ expression (r=0.712, p<0.001) in the same groups. The Th1 response was dominant in pre-treatment states, and then it shifted to a Th2 dominant state after IFN-β treatment. CONCLUSION We suggest that the chemokine receptor expression of Th1/Th2 cell subsets could be used for monitoring and the evaluation of the MS disease status.